Telomir Pharmaceuticals, Inc. (TELO) Stock Statistics & Valuation Metrics

Telomir Pharmaceuticals, Inc. has a market cap or net worth of $42.29M. The enterprise value is ―.

Telomir Pharmaceuticals, Inc. has 32,280,970 shares outstanding. The number of shares has decreased by -2.65% in one year.

Telomir Pharmaceuticals, Inc.’s return on equity (ROE) is -25.71 and return on invested capital (ROIC) is -1662.28%.

The current PE Ratio of Telomir Pharmaceuticals, Inc. is ―. Telomir Pharmaceuticals, Inc.’s PEG ratio is -0.27.

In the last 12 months, Telomir Pharmaceuticals, Inc. had revenue of 0.00 and earned -16.53M in profits. Earnings per share was -0.56.

In the last 12 months, operating cash flow was -3.17M and capital expenditures 4.00, giving a free cash flow of -3.17M billion.

Telomir Pharmaceuticals, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Telomir Pharmaceuticals, Inc. upcoming earnings date is ―, ―.

Telomir Pharmaceuticals, Inc. as a current ratio of 1.94, with Debt / Equity ratio of 0.00%

In the past 12 months, Telomir Pharmaceuticals, Inc. has paid 0.00 in taxes.

Telomir Pharmaceuticals, Inc. EV to EBITDA ratio is -9.88, with an EV/FCF ratio of -23.77.

Telomir Pharmaceuticals, Inc. has $754.32K in cash and marketable securities with $0.00 in debt, giving a net cash position of $754.32K billion.

Gross margin is 18.04%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Telomir Pharmaceuticals, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy